InnoCan Pharma Statistics
Total Valuation
InnoCan Pharma has a market cap or net worth of 44.70 million. The enterprise value is 41.35 million.
| Market Cap | 44.70M |
| Enterprise Value | 41.35M |
Important Dates
The last earnings date was Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 292.42M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +7.00% |
| Shares Change (QoQ) | +1.61% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 291.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.55 |
| PB Ratio | 6.68 |
| P/TBV Ratio | 10.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 118.32, with an EV/FCF ratio of -88.16.
| EV / Earnings | -26.24 |
| EV / Sales | 1.44 |
| EV / EBITDA | 118.32 |
| EV / EBIT | 130.98 |
| EV / FCF | -88.16 |
Financial Position
The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.21.
| Current Ratio | 3.70 |
| Quick Ratio | 2.70 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 3.97 |
| Debt / FCF | -2.98 |
| Interest Coverage | 26.50 |
Financial Efficiency
Return on equity (ROE) is -4.84% and return on invested capital (ROIC) is 2.81%.
| Return on Equity (ROE) | -4.84% |
| Return on Assets (ROA) | 2.01% |
| Return on Invested Capital (ROIC) | 2.81% |
| Return on Capital Employed (ROCE) | 3.93% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 2.92 |
| Inventory Turnover | 1.26 |
Taxes
In the past 12 months, InnoCan Pharma has paid 937,000 in taxes.
| Income Tax | 937,000 |
| Effective Tax Rate | 148.97% |
Stock Price Statistics
The stock price has decreased by -13.89% in the last 52 weeks. The beta is -0.38, so InnoCan Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.38 |
| 52-Week Price Change | -13.89% |
| 50-Day Moving Average | 0.14 |
| 200-Day Moving Average | 0.14 |
| Relative Strength Index (RSI) | 59.81 |
| Average Volume (20 Days) | 382 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCan Pharma had revenue of 28.83 million and -1.58 million in losses. Loss per share was -0.01.
| Revenue | 28.83M |
| Gross Profit | 25.50M |
| Operating Income | 318,000 |
| Pretax Income | 629,000 |
| Net Income | -1.58M |
| EBITDA | 352,000 |
| EBIT | 318,000 |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 7.26 million in cash and 1.40 million in debt, giving a net cash position of 5.86 million.
| Cash & Cash Equivalents | 7.26M |
| Total Debt | 1.40M |
| Net Cash | 5.86M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.69M |
| Book Value Per Share | 0.01 |
| Working Capital | 7.98M |
Cash Flow
In the last 12 months, operating cash flow was -453,000 and capital expenditures -16,000, giving a free cash flow of -469,000.
| Operating Cash Flow | -453,000 |
| Capital Expenditures | -16,000 |
| Free Cash Flow | -469,000 |
| FCF Per Share | n/a |
Margins
Gross margin is 88.45%, with operating and profit margins of 1.10% and -5.47%.
| Gross Margin | 88.45% |
| Operating Margin | 1.10% |
| Pretax Margin | 2.18% |
| Profit Margin | -5.47% |
| EBITDA Margin | 1.22% |
| EBIT Margin | 1.10% |
| FCF Margin | n/a |
Dividends & Yields
InnoCan Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.00% |
| Shareholder Yield | n/a |
| Earnings Yield | -3.53% |
| FCF Yield | -1.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InnoCan Pharma has an Altman Z-Score of 4.9 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.9 |
| Piotroski F-Score | 3 |